Raj Chovatiya, MD, PhD, MSCI

Chovatiya acknowledged the common sentiment among residents who, despite dedicating significant time to studying and working during residency, may feel unprepared.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the tolerability and low discontinuation rates of tapinarof for patients in AD clinical trials, as well as discuss the adverse events associated with the drug.

Adelaide A. Hebert, MD, FAAD, shares insight on the eczema area and severity index 75 (EASI75) results from the ADORING 1 and ADORING 2 clinical trials for use of tapinarof in AD.

Expert dermatologists review the validated investigator global assessment for AD (vIGA-AD) response in the ADORING 1 and ADORING 2 trials for tapinarof.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the rapid itch reduction results found in the clinical trials for tapinarof in AD, as well as primary end points of the studies.

Expert dermatologists highlight the patient characteristics in the ADORING 1 and ADORING 2 trials, both focusing on tapinarof for the treatment of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review clinical trial data for tapinarof cream, 1% in the treatment of AD.

Expert dermatologists discuss the use of nonsteroidal treatment formulations for the treatment of AD, focusing on a topical treatment, tapinarof cream, 1%.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had in managing the disease.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the current treatment landscape of atopic dermatitis (AD), as well as key factors when selecting treatment for patients with the disease.

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

Raj Chovatiya, MD, PhD, reviews a case of an adolescent patient with rapid changes in existing vitiligo.

Boni Elewski, MD, shares resources for patients with GPP, highlighting a team-based approach to meet the psychological and physical needs of the patient.

Drs Raj Chovatiya and Boni Elewski comment on the future of combination therapy in GPP, highlighting spesolimab.

Raj Chovatiya, MD, PhD, shares his atopic dermatitis insights.

Raj Chovatiya, MD, PHD, and Boni Elewski, MD, discuss long-term treatment selection for a patient whose GPP flare cleared with 1 infusion of spesolimab.

Boni Elewski, MD, reviews a case of a woman in the emergency department with a severe GPP flare.

He delves into one of his most challenging recent cases, the evolution of treatment options, and strategies to think outside of the box in diagnostic and therapeutic approaches.

Boni Elewski, MD, shares her personal experience using generalized pustular psoriasis treatments in the clinical setting.

Drs Raj Chovatiya and Boni Elewski discuss a patient case and the challenges of diagnosing generalized pustular psoriasis (GPP), commenting on the many types of psoriasis and treatment.

Expert dermatologists review a case of a 61-year-old female patient with GPP with no personal or family history of the condition.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, reviews the many pathways of generalized pustular psoriasis (GPP), focusing on individualizing therapy for patients with GPP and treatment options.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, define what differentiates generalized pustular psoriasis (GPP) from other forms of psoriasis and discuss tools for diagnosing GPP.

As the 25th World Congress of Dermatology winds down this week, Chovatiya shares highlights from his sessions in Singapore.

Renata Block, PA-C; Raj Chovatiya, MD, PhD; and Zoe Diana Draelos, MD, discuss their optimism and concerns surrounding the increased use of artificial intelligence in dermatology.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.

Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss take a closer look at the TRuE-AD1 and TRuE AD2 phase 3 trial and provide context regarding ruxolitinib cream for the treatment of atopic dermatitis in the clinical setting.